124 EMAS2017 / Maturitas 100 (2017) 93–202 Jump02 Evaluation of sexual function in mid-aged Ecuadorian women using the six-item Female Sexual Function Index Anastasia Armeni 1,∗ , Danny Salazar-Pousada 2 , Sofía S. Andrade-Ponce 2 , Juan C. Tupacyupanqui-Mera 2 , Faustino R. Pérez-López 3 , Peter Chedraui 2 1 Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Patras Medical School, Patras, Greece 2 Institute of Biomedicine, Facultad de Medicina, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador 3 University of Zaragoza, Faculty of Medicine, Zaragoza, Spain Objective: To assess sexual function and related factors (includ- ing metabolic ones) in a sample of mid-aged women. Methods: In this cross-sectional study, 202 urban-living women from Guayaquil (Ecuador), 40–69 years, were surveyed with the six-item version of the Female Sexual Function Index (FSFI-6) and a questionnaire containing personal and partner data. In addition, abdominal circumference and serum metabolic parameters were assessed. Results: The median age of the sample was 50 years, 56.9% were postmenopausal, 5.9% used hormone therapy, 3% psychotropic drugs, 36.6% had hypertension, 4.5% hyperglycemia, 50% abdom- inal obesity, 17.3% had the metabolic syndrome (METS) and 67.3% had a partner (n = 136). Overall, 38.6% (78/202) of surveyed women were sexually active, presenting a median total FSFI-6 score of 19.0. Lower total FSFI-6 scores were associated to several factors such as age, educational level, menopausal status and coital fre- quency (bivariate analysis); while no association was found with the presence of the METS or its components. Multiple linear regres- sion analysis found that higher total FSFI-6 scores, indicating better sexual function, were significantly correlated to coital frequency; whereas age and postmenopausal status inversely correlated to total FSFI-6 scores, indicating worse sexual function. Conclusion: As determined with the FSFI-6, sexual function of this mid-aged urban female Ecuadorian sample was related to coital frequency, age and postmenopausal status. http://dx.doi.org/10.1016/j.maturitas.2017.03.266 Jump03 Androgen supplementation for hypoactive sexual desire disorder in postmenopausal women: A systematic review and meta-analysis D. Filipowicz 1,∗ , M. Nigdelis 2 , B. Meczekalski 3 , D.G. Goulis 2 1 Poznan University of Medical Sciences, Students’ Scientific Society of the Department of Gynecological Endocrinology, Poznan, Poland 2 Aristotle University of Thessaloniki, Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Thessaloniki, Greece 3 Poznan University of Medical Sciences, Department of Gynecological Endocrinology, Poznan, Poland Context: Postmenopausal period has been associated with increased prevalence of Hypoactive Sexual Desire Disorder (HSDD). Although androgen supplementation, on top of estrogen replace- ment therapy (ERT), has been proposed as possible treatment for HSDD, data are conflicting. Objective: To evaluate the best available evidence concern- ing the effect of androgen supplementation (per os, transvaginal testosterone; dehydroepiandrosterone sulfate (DHEA-S); tibolone] on HSDD in postmenopausal women and to meta-analyze data from randomized controlled trials asking this specific research question. Methods: PubMed, EMBASE and Cochrane electronic databases were comprehensively searched from conception until December 2016. Six RCTs fulfilled the inclusion criteria and were included in the meta-analysis. Data extraction and risk of bias assessment was performed in duplicate for each study. Three scales of Female Sexual Function Index (FSFI) [FSFI-(D)esire, FSFI-(A)rousal, FSFI- (T)otal] were used to quantify HSDD. The random effect model was applied. Meta-analysis was conducted by R Studio for Mac (version 1.0.44). Results: Androgen supplementation resulted in increase in FSFI-D [mean difference (MD) 1.01, 95% confidence interval (CI) 0.42–1.60, p < 0.001, heterogeneity (I 2 ) 90.5%], FSFI-A (MD 1.00, 95% CI 0.74–1.26, p < 0.001, I 2 0%) and FSFI-T (MD 3.45, 95% CI -1.73 to 8.63, p > 0.05, I 2 94.5%). Publication bias, sensitivity anal- ysis, subgroup analysis (according to type of menopause and type of androgen) and meta-regression (moderators: age, years since menopause, body mass index, dosage of androgen) techniques were used to explain heterogeneity among studies. Conclusions: Androgen supplementation results in improved HSDD parameters. Therefore, it should be considered in the treat- ment of postmenopausal women with HSDD. This study has been conducted in the frame of EMAS mentoring program (JuMP). http://dx.doi.org/10.1016/j.maturitas.2017.03.267 Jump04 Parathyroid hormone levels in menopause: Associations with demographic characteristics, calcium supplementation and sex hormone profile Nikolaos Athanasopoulos 1,∗ , Areti Augoulea 1 , Aikaterini Kazani 1 , Paraskevi Pliatsika 1 , Nikolaos Tsoltos 1 , Irene Lambrinoudaki 1 , Serge Rozenberg 2 1 National and Kapodistrian University of Athens, 2nd Department of Obstetrics and Gynecology, Medical School, Athens, Greece 2 CHU Saint-Pierre, UMC Sint-Pieter, Brussels, Belgium Aim: The aim of the study was to investigate possible determi- nants of circulating parathyroid hormone (PTH) in a sample of peri- and postmenopausal women. Methods: This is a retrospective analysis of 538 charts of peri- and post-menopausal women from a Menopause Clinic. Charts of women known to have premature ovarian failure, gyneco- logical malignancy, clinically overt or treated CVD, VTE, familial hypercholesterolemia, inflammatory disease, diabetes or hyper- parathyroidism were excluded from the study. A complete medical history was obtained, including anthropometric measurements. Laboratory measurements included PTH, Testosterone, E2, FSH, LH, SHBG, as well as 25(OH)-vitamin D and Calcium levels. Results: 117 women were using Calcium and Vit.D supple- mentation, while 421 patients served as controls. No significant differences were noted in PTH levels, as well as in the hormonal pro- file between the two groups. Vitamin D was more elevated in the